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In this issue of Cancer Cell, Melo et al. show that mutation of a single allele of the Exportin-5 gene (XPO5)
suffices to depress microRNA (miRNA) levels and promote tumorigenesis. Thus, XPO5 joins the ranks of
DICER and TRBP as a haploinsufficient tumor suppressor in the miRNA biogenesis pathway.MicroRNAs are regulatory RNAs that
silence mRNAs in a sequence-specific
manner. Originally discovered in Caeno-
rhabditis elegans, almost a thousand
different human miRNAs are now known
to repress a vast array of target mRNAs.
As these include both oncogenes and
tumor suppressors, dysregulation of
miRNAs contributes to various cancers
(Chang and Mendell, 2007). However,
the causes of miRNA dysregulation are
frequently unclear, particularly in those
tumors where the levels of many or all
miRNAs are changed. Possibly, such
alterations reflect defects in the general
miRNA biogenesis pathway.
MicroRNA biogenesis begins with the
transcription of long primary miRNAs
(Figure 1) (Kim et al., 2009). These pri-
miRNAs are processed by the ribonu-
clease DROSHA (aka RNASEN) and its
cofactor DGCR8/Pasha into the hairpin-
shaped precursor miRNAs. DICER, in
a complex with its partners TRBP or
PACT, further processes the pre-miRNAs
into short RNA duplexes. One of the
duplex strands binds to an Argonaute
protein to form an miRNA-induced
silencing complex (miRISC), which
represses target mRNAs through transla-
tional repression and degradation.
While pri-miRNAprocessing is anuclear
event, pre-miRNA processing occurs in
the cytoplasm. Thus, pre-miRNAs need
to transit from the nucleus into the cyto-
plasm, a process that requires the nuclear
export receptor XPO5. Melo et al. (2010)
now identify XPO5 as a haploinsufficient
tumor suppressor in a subset of cancers
with microsatellite instability (MSI+).
These cancers are characterized by
expansion or contraction of short DNArepeats due to defects in the DNA
mismatch repair system (Boland and
Goel, 2010). In protein-coding se-
quences, frame-shift mutations result,
which may render affected proteins
nonfunctional and thus drive cancerogen-
esis through inactivation of tumor sup-
pressor genes. MSI is particularly
frequent in colorectal cancer (CRC),
where it accounts for a combined total
of 15% of sporadic and heritable cases,
but also affects other sites.
Melo et al. (2010) report that XPO5 is
mutated in some MSI+ cell lines and
primary tumors. Expansion of an (A)7
microsatellite in exon 32 alters and trun-
cates the protein sequence and prevents
XPO5 from both associating with its pre-
miRNA cargo and exiting the nucleus. In
XPO5mut/+ heterozygous cells, less pre-
miRNA was hence accessible to process-
ing by DICER, resulting in decreased
mature miRNA levels. The defects ap-
peared to reflect loss, not neomorphic
gain, of XPO5 function, since modest
overexpression of wild-type XPO5
rescued the pre-miRNA export and pro-
cessing defects. Interestingly, although
the heterozygous XPO5 mutation de-
creased accumulation of a large fraction
(20%) of detectable miRNAs, many
others remained unaffected. It thus
appears possible that XPO5 does not
bind to pre-miRNAs indiscriminately but
has certain substrate preferences,
perhaps mediated by sequence or struc-
ture. Downregulated miRNAs might then
be those that bind poorly to XPO5 and
thus cannot compete well for export by
limiting amounts of XPO5. Alternatively,
additional nuclear export pathways might
be available to miRNAs that remainedCancer Cell 18unaffected, as suggested by recent work
in C. elegans (Bu¨ssing et al., 2010).
Several genes have been identified
that are affected by MSI, but it is not
always clear which of these are ‘‘driver
mutations’’ that truly contribute to tumor-
igenesis and which are ‘‘passenger
mutations’’ that signal the presence of
a DNA repair defect but have little impact
on tumorigenesis (Boland and Goel,
2010). Knudson’s ‘‘two-hit’’ model offers
a possible distinction (Payne and Kemp,
2005). It postulates that only inactivation
of both alleles of a tumor suppressor
genes (the two hits) provides cells with
a selective advantage. Hence, true tumor
suppressor genes will frequently display
loss of heterozygosity (LOH), i.e., lose
the remaining wild-type allele, in tumors.
By contrast, lack of selective pressure
on passenger mutations would typically
cause these to remain heterozygous.
By this criterion, XPO5 would miss the
bar. XPO5 LOH could be observed neither
in cell lines nor primary tumors. However,
recent work has suggested that other
components of the miRNA biogenesis
pathway, DICER and TRBP (encoded by
the TARBP2 gene), are haploinsufficient
tumor suppressors (Kumar et al., 2009;
Melo et al., 2009; Hill et al., 2009). More-
over, biallelic deletion impaired cell
viability, hence preventing LOH. This
appears also true for XPO5: mimicking
XPO5 LOH by RNA interference (RNAi)
against the XPO5 wild-type allele in
XPO5mut/+cells impairedcellviability.Con-
versely, supplementation of XPO5mut/+
cellswithwild-typeXPO5 fromatransgene
restored miRNA biogenesis to the wild-
type situation and reduced tumorigenicity.
Thus, it seems that at least three, October 19, 2010 ª2010 Elsevier Inc. 295
Figure 1. XPO5 Haploinsufficiency Impairs miRNA Biogenesis and Promotes Tumorigenesis
(A) Schematic depiction of themiRNA biogenesis pathway. Some relevant proteins are indicated. XPO5mediates nuclear export of pre-miRNAs in a complex with
RanGTP; this complex disassembles in the cytoplasm upon hydrolysis of GTP to GDP. A bolt marks haploinsufficient tumor suppressors, which include XPO5.
(B) Functional pre-miRNA export in XPO5+/+ wild-type cells sustains the mature miRNA levels that are required to control cell differentiation and proliferation.
Impaired pre-miRNA export in XPO5mut/+ heterozygous mutant cells depletes mature miRNAs and is tumorigenic but can be overcome by expression of addi-
tional wild-type XPO5. This, and the fact that partial depletion of XPO5 by RNAi mimics XPO5mut/+ heterozygosity, is consistent with haploinsufficiency rather than
mutant gain of function causing the defects.
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pathway are haploinsufficient tumor
suppressors, with XPO5 and TARBP2
but not DICER mutations prevalent in
MSI+ tumors (Melo et al., 2009; 2010). In
addition, the miRISC components AGO2,
TNRC6A, and TNRC6C can be mutated
in MSI+ cancers (Kim et al., 2010),
although functional consequences remain
to be evaluated.
Is the case closed for XPO5 and TRBP
as haploinsufficient tumor suppressors
in MSI+ cancers? Not quite. So far, tumor
suppressive function has been observed
in vitro and in an allograft nude mouse
model. In a next step, it will be important
to demonstrate this function in XPO5+/
and TARBP2+/ hemizygous mice,
respectively. Are these mice more prone296 Cancer Cell 18, October 19, 2010 ª2010to tumors, as observed for DICER+/
mice? If so, what kinds of tumors occur:
gastrointestinal tumors as might be ex-
pected if the frequent XPO5 and TARBP2
mutations in MSI+ cancers are conse-
quences of specific selective pressures
on these tumors? Would these mutations
be more synergistic with CRC driver
mutations than with mutations driving
other tumors? Conversely, are XPO5 and
TARBP2 subject to increased MSI rates
in MSI+ mouse models? If so, it may be
possible to establish whether miRNA defi-
ciency occurs at a specific point during
tumorigenesis, perhaps driving one or
more select events on the path to cancer.
Regardless of these possibilities, one
important implication of the two studies
by Melo et al. (2009, 2010) is that almostElsevier Inc.half of all MSI+ tumors carry defects in
their miRNA biogenesis machineries:
among 337 primary tumor samples
analyzed, some 23% carried one of three
different microsatellite mutations in exon
32 of XPO5, all of which impaired XPO5
localization and miRNA biogenic activity,
and some 26% of 282 primary tumor
samples contained either one of two mi-
crosatellite mutations found to inactivate
TRBP. Mutations in TARBP2 and XPO5
appear mutually exclusive. The presence
of mutations in miRNA pathway genes in
MSI+ cancer samples, albeit at a lower
frequency, has also been reported in
a separate study of Korean patients (Kim
et al., 2010). This begs the question of
whether this pathway just makes a conve-
nient target or whether a deeper
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Previewsunderlying rationale exists where miRNA
depletion causes particular proliferative
or survival advantages in these cancers.
Indeed, it seems rather mysterious that
a pathway that is considered important
to provide robustness to gene expression
programs would display itself so little
robustness to mutational assault. It will
therefore be of particular interest to
examine whether haploinsufficiency is
a general feature of miRNA pathway
genes across various cancer sites and
types or more closely restricted to MSI+
tumors.
Finally, it remains to be seen whether
the new findings can be exploited thera-
peutically. At this point, short of gene
therapy, there seems to be little that can
be done to target the XPO5 defect directly
so that restoring miRNA accumulation by
alternative routes might be a more real-istic approach. Provided that only one or
few of the deregulated miRNAs are
responsible for the tumor-promoting
effect of XPO5 mutation, it may be
possible to supply them exogenously as
miRNA duplexes that would not need to
undergo nuclear export. Alternatively, it
may be possible to identify a subset of
key targets of the deregulated miRNAs
that might be amenable to inactivation
through classical pharmacological
approaches or novel biologics.
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T cell precursor malignancies may present as T-lymphoblastic lymphoma (T-LBL) with marked enlargement
of lymph nodes or acute T-lymphoblastic leukemia (T-ALL) with little lymph node enlargement. In this issue
of Cancer Cell, Feng et al. show that dysregulation of BCL2, AKT signaling, and cell adhesion pathways are
hallmarks of T-LBL.T-lineage lymphoblastic lymphoma (T-
LBL) and acute lymphoblastic leukemia
(T-ALL) represent up to 15%–25% of
cases of ALL in children and adults and
exhibit a remarkable spectrum of clinical,
pathologic, and genetic features. In
contrast to B-progenitor ALL, in which
extensive bone marrow involvement at
presentation is a near universal feature
and significant lymph node enlargement
is uncommon, patients with T-lineage
disease frequently present with marked
lymph node enlargement in the chest
(mediastinal masses), often with minimal
or absent bone marrow involvement
(Figure 1). Traditionally, patients witha mediastinal mass and less than 25%
leukemic cells (blasts) in the bone marrow
are deemed to have T-LBL; those with
a high marrow burden, T-ALL. While this
distinction may appear somewhat arbi-
trary, a notable observation is that
patients with large mediastinal masses
frequently exhibit little, if any, evidence
of tumor dissemination and marrow
involvement, and the basis for this is
unknown.
Both T-LBL and T-ALL cases com-
monly harbor chromosomal rearrange-
ments, submicroscopic DNA copy num-
ber alterations, and sequence mutations.
These alterations commonly dysregulateor disrupt genes with key roles in hemato-
poietic development, lymphoid differenti-
ation, cell cycle regulation, and tumor
suppression and are key events in leuke-
mogenesis (e.g., rearrangements of
T cell antigen receptor genes, HOX11L1
and HOX11L2, TAL1, LYL1, mutation of
NOTCH1 and FBXW7, and deletion or
mutation of PTEN and WT1) (Aifantis
et al., 2008). However, in contrast to
B-progenitor ALL, in which specific
genetic alterations such as mutation of
the lymphoid transcription factor IKZF1
are strongly associated with poor prog-
nosis (Mullighan et al., 2009), identifica-
tion of features that predict clinical, October 19, 2010 ª2010 Elsevier Inc. 297
